Metformin and Fasting May Protect Kidneys in Rat Study
New research explores if these interventions could mitigate chemotherapy-related kidney damage in animal models.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Do you trust that animal-based medical research generally translates into reliable benefits for human health?
A new study in rats suggests that both metformin and intermittent fasting may help protect against kidney damage caused by the chemotherapy drug cisplatin. Researchers found that both interventions improved markers of renal function in the study subjects.
Why it matters
Cisplatin is a common chemotherapy drug known to cause kidney injury, prompting research into strategies that might mitigate this side effect. Understanding these potential protective mechanisms could eventually help guide supportive care approaches during cancer treatment.
This study of 24 adult male rats utilized a controlled comparison to assess renal health after cisplatin exposure. Because the results are based on preclinical animal models, they remain preliminary and do not confirm effectiveness or safety in human patients.
The details
The study examined how metformin and intermittent fasting might modulate mitophagy, a cellular quality-control process, to defend kidney cells. By analyzing gene expression for markers like PINK1 and Parkin, researchers observed that these interventions helped restore balance in cellular pathways disrupted by cisplatin. This reduction in oxidative stress and improved clearance of damaged cellular components appeared to support better overall kidney function.
Timeline
Cisplatin was administered to the rat subjects on day eight.
The oral metformin treatment lasted for 12 days.
Health Landscape
This work sits within the established field of nephrotoxicity research, which aims to minimize organ damage during necessary chemotherapy regimens. It contributes to the evolving investigation of whether metabolic pathways can be manipulated to improve patient resilience during treatment.
These findings are strictly limited to an animal model and do not support using metformin or intermittent fasting for kidney protection in humans. If you are undergoing chemotherapy, always discuss potential supportive care strategies or dietary changes with your oncology team.
The takeaway
While this study provides insights into how certain metabolic interventions may protect kidney function in preclinical settings, it does not provide clinical guidance for patients. Patients should consult their physician before making any changes to their medical treatment or diet during chemotherapy.
Further reading
Learn more about the latest research on dietary patterns and metabolic health in the Nutrition section.
More information
You can view the original peer-reviewed research article to learn more about the study design.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that animal-based medical research generally translates into reliable benefits for human health?
